NantHealth, Inc. (NASDAQ:NH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Increase in Number of Directors; Appointment of Director
Effective March 11, 2020, the board of directors (the “Board”) of NantHealth, Inc. (the “Company”), to the Company’s Bylaws, increased the number of directors from five to six and appointed Deanna Wise to the Board with a term expiring at the Company’s 2020 annual meeting of stockholders.
Ms. Wise, age 51, joined Banner Health, a non-profit health system based in Phoenix, Arizona, in 2019 and is currently its Senior Vice President and Chief Information Officer. Between May 2011 and December 2018, Ms. Wise served as Executive Vice President and Chief Information Officer at Dignity Health, a California-based not-for-profit public benefit corporation. Before joining Dignity Health, between October 2006 and March 2011, Ms. Wise served as the Senior Vice President and Chief Information Officer for Vanguard Health Systems (NYSE: VHS). Prior to this role, between August 2004 and October 2006, Ms. Wise was the Chief Information Officer for Vanguard’s Abrazo Health Care Phoenix market. Prior to joining Abrazo Health Care, between November 2002 and August 2004, Ms. Wise served as the Chief Information Officer for the Maricopa County Health District. Ms. Wise earned a computer science degree and is a Project Management Professional (PMP) certified member of the Professional Management Institute (PMI). Ms. Wise was also inducted into the 2018 CIO Hall of Fame. We believe that Ms. Wise is qualified to serve as a member of our board of directors because of her extensive experience and knowledge in the hospital and health care industry and her extensive experience in implementing, managing and operating complex information technology systems and information security programs.
In accordance with the Company’s outside director compensation policy (the “Outside Director Compensation Policy”), Ms. Wise was granted a restricted stock unit award (the “RSU”) on March 11, 2020 with a value of $325,000, vesting annually over a three year period, in each case subject to Ms. Wise’s continued service to the Company. The RSU award is subject to the terms and conditions of the Company’s 2016 Equity Incentive Plan and the related RSU agreement. Beginning at the Company’s annual meeting of stockholders in 2021, Ms. Wise will also be eligible for equity award grants on the same terms as other non-employee members of the Board, including an annual grant of an option to purchase shares of the Company’s common stock for continuing directors with a value of $100,000, vesting on the earlier of (i) the one year anniversary of the grant or (ii) the day prior to the date of the Company’s annual meeting of stockholders following the date of grant, provided that such non-employee director continues to serve as a service provider through the applicable vesting date.
Furthermore, Ms. Wise is entitled to receive cash compensation in accordance with the terms and conditions of the Company’s Outside Director Compensation Policy. Under the Outside Director Compensation Policy, each non-employee director receives cash compensation of $50,000 annually for service as a Board member; $10,000 per year additionally for service as an audit committee member; $7,500 per year additionally for service as a member of the compensation committee; $15,000 per year as a member of the special committee; $10,000 per year additionally for service as chairperson of the audit committee; $7,500 per year additionally for service as chairperson of the compensation committee; and $15,000 per year additionally for service as chairperson of the special committee. We will also reimburse Ms. Wise for all reasonable expenses in connection with her services to us.
Ms. Wise executed the Company’s standard form of indemnification agreement.
There is no arrangement or understanding between Ms. Wise and any other persons to which Ms. Wise was selected as a director. In addition, Ms. Wise is not a party to any transaction, or series of transactions, required to be disclosed to Item 404(a) of Regulation S-K.
A copy of the press release issued by the Company on March 12, 2020 regarding the above is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 5.02.
2020 Goals and Objectives; Changes in Executive Compensation
On March 10, 2020, the compensation committee of the Board reviewed and approved metrics with regard to the chief financial officer and chief operating officer’s target annual bonus relating to the Company’s goals for 2020 such as: revenue, earnings, cash flow, development/quality of products and human resources matters. On March 10, 2020, the compensation committee of the Board adopted and approved (i) an increase to the base salary of Bob Petrou, the Company’s chief financial officer, to $348,400 per year, effective March 16, 2020, with a potential cash bonus of up to 50% of his base salary for the year ending December 31, 2020 and (ii) an increase to the base salary of Ronald A. Louks, the Company’s chief operating officer, to $475,200 per year, effective March 16, 2020, with a potential cash bonus of up to 75% of his base salary for the year ending December 31, 2020.
NantHealth, Inc. Exhibit
EX-99.1 2 a99103132020.htm EXHIBIT 99.1 Exhibit Exhibit 99.1NANTHEALTH ANNOUNCES APPOINTMENT OF DEANNA L. WISE TO ITS BOARD OF DIRECTORSNew board member brings clinical expertise and IT leadership Culver City,…
To view the full exhibit click
About NantHealth, Inc. (NASDAQ:NH)
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
An ad to help with our costs